Retatrutide 40mg Peptide-Synedica
Retatrutide 40mg Peptide-Synedica - Image 2
Retatrutide 40mg Peptide-Synedica - Image 3
Retatrutide 40mg Peptide-Synedica - Image 4

Retatrutide 40mg Peptide-Synedica

£ 220

Retatrutide 40mg Injection Pen Kit non-medical, R&D use

Function: Triple-agonist peptide designed to support scientific studies involving metabolic signaling, appetite regulation, and energy-balance pathways.

Focus: Used in controlled laboratory research examining GLP-1, GIP, and glucagon-receptor interactions, as well as their combined influence on weight-management mechanisms.

Status: Research-grade investigational compound intended exclusively for laboratory and educational use. Not approved for human consumption, medical treatment, or therapeutic applications.

Category: Brand:

Description

Synedica Retatrutide Injection Pen Kit represents one of the most advanced solutions in modern medical weight management. Retatrutide is a next-generation triple-agonist therapy that reduces appetite and promotes significant weight loss. It works by activating the GLP-1, GIP, and glucagon receptors—natural hormonal pathways responsible for satiety and appetite control. This allows users to feel full after much smaller meals.

The Synedica Retatrutide 40mg Injection Pen Kit includes:

  • 1 injection pen

  • 12 disposable needles

  • 1 instruction booklet

Each pen contains 40mg, which can be administered as 4 doses of 10mg, or in adjustable increments of 2.5mg, 5mg, 7.5mg, or 10mg.

Recommended Dosing Schedule

  • Weeks 1–4: 2.5mg weekly

  • Weeks 5–8: 5mg weekly

  • After Week 8: Dose may be increased to 7.5mg or 10mg if required and tolerated

Important: Always seek professional medical guidance before starting any new medication.

The Synedica Retatrutide 40mg Injection Pen Kit is stocked at selected pharmacies across Germany and may be availablefree of charge for eligible individuals covered under Gesetzliche Krankenversicherung (GKV).

Product Description

What Is the Synedica Retatrutide Injection Pen Kit?

The Synedica Retatrutide Injection Pen Kit is considered one of the most effective treatments in advanced weight-loss therapy. Retatrutide is a triple-receptor agonist targeting GLP-1, GIP, and GCGR pathways. Together, these mechanisms help curb appetite, reduce cravings, and enhance metabolic regulation—providing more powerful results than traditional single-pathway GLP-1 medications.
For new users, one kit typically provides approximately 12 weeks of treatment.

Key Benefits

  • Activates three metabolic receptors for improved weight-loss outcomes
  • Helps control hunger and daily food cravings
  • Supports fast and long-lasting fat reduction
  • Reduces the feeling of constant hunger often associated with dieting

Common Side Effects

Some users may temporarily experience nausea, jaw discomfort, or low mood. Full safety information and a comprehensive list of side effects are included in the instruction booklet.

What’s Included

  • 1 Ă— Retatrutide injection pen
  • 12 Ă— 32G 4mm disposable needles
  • 1 Ă— instruction manual

Pricing & Availability

  • Approx. €600 per kit (around 12 weeks of treatment) in private pharmacies
  • May be covered under employer health programs or GKV for qualified individuals
  • Available by prescription only in Germany

Which Treatment Should You Begin With?

  • Semaglutide (Ozempic/Wegovy): First-line option, GLP-1 agonist
  • Tirzepatide (Mounjaro): Second-line, dual agonist (GLP-1 + GIP)
  • Retatrutide: Most advanced, triple agonist (GLP-1 + GIP + GCGR), generally recommended for patients who no longer respond adequately to tirzepatide

Related products